Pioglitazone: an antidiabetic drug with the potency to reduce cardiovascular mortality

Bibliography

• KING H, AUBERT RE, HERMANN WH: Global Burden of Diabetes – 1995 – 2025: prevalence, numerical estimates, and projections. Diabetes Care (1998) 21:1414-1431.
   PubMed Web of Science ®Google Scholar
• FERRANNINI E: Insulin resistance versus insulin deficiency in non-insulin-dependent diabetes mellitus: problems and prospects. Endocr. Rev. (1998) 19:477-490.
   PubMed Web of Science ®Google Scholar
• YKI-JÄRVINEN H: Pathogenesis of non-insulin-dependent diabetes mellitus. Lancet (1994) 94:91-95.
   Google Scholar
• PFÜTZNER A, KANN P, PFÜTZNER AH et al.: Intact and total proinsulin: new aspects for diagnosis and treatment of Type 2 diabetes. Clin. Lab. (2004) 50:567-573.
   PubMedGoogle Scholar
• AMERICAN DIABETES ASSOCIATION: Diagnosis and classification of diabetes mellitus. Diabetes Care (2005) 28:S37-S42.
   PubMed Web of Science ®Google Scholar
• YKI-JARVINEN H: Insulin resistance and endothelial dysfunction. Best Pract. Res. Clin. Endocrinol. Metab. (2003) 17:411-430.
   PubMed Web of Science ®Google Scholar
• AMERICAN DIABETES ASSOCIATION: Standards of medical care in diabetes. Diabetes Care (2005) 28(Suppl. 1):S4-S36. Erratum in: Diabetes Care (2005) 28:990.
   PubMed Web of Science ®Google Scholar
• DIAMANT M, HEINE RJ: Thiazolidinediones in Type 2 diabetes mellitus: current clinical evidence. Drugs (2003) 63:1373-1405.
   PubMed Web of Science ®Google Scholar
• PLOSKER GL, FAULDS D: Troglitazone: a review of its use in the management of Type 2 diabetes mellitus. Drugs (1999) 57:409-438.
   PubMed Web of Science ®Google Scholar
• SCHEEN AJ: Thiazolidinediones and liver toxicity. Diabetes Metab. (2001) 27:305-313.
   PubMed Web of Science ®Google Scholar
• VASUDEVAN AR, BALASUBRAMANYAM A: Thiazolidinediones: a review of their mechanisms of insulin sensitization, therapeutic potential, clinical efficacy, and tolerability. Diabetes Technol. Ther. (2004) 6:850-863.
   PubMedGoogle Scholar
• GRANBERRY MC, FONSECA VA: Cardiovascular risk factors associated with insulin resistance: effects of oral antidiabetic agents. Am. J. Cardiovasc. Drugs (2005) 5:201-209.
   PubMedGoogle Scholar
• PFÜTZNER A, SCHÖNDORF T, SEIDEL D et al.: Impact of rosiglitazone on β-cell function, insulin resistance and adiponectin concentrations – results from a double blind oral combination study with glimepiride. Metabolism (2006) 55:20-25.
   PubMed Web of Science ®Google Scholar
• GOLDBERG RB, KENDALL DM, DEEG MA et al.: A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with Type 2 diabetes and dyslipidemia. Diabetes Care (2005) 28:1547-1554.
   PubMed Web of Science ®Google Scholar
• WELLINGTON K: Rosiglitazone/metformin. Drugs (2005) 65:1581-1592.
   PubMed Web of Science ®Google Scholar
• BARLOCCO D: Muraglitazaar (Bristol-Myers Squibb/Merck). Curr. Opin. Investig. Drugs. (2005) 6:427-434.
   PubMedGoogle Scholar
• KAMBER N, DAVIS TM: Tesaglitazaar (AstraZeneca). IDrugs (2005) 8:927-935.
   PubMed Web of Science ®Google Scholar
• NISSEN SE, WOLSKI K, TOPOL EJ: Effect of muraglitazaar on death and major adverse cardiovascular events in patients with Type 2 diabetes mellitus. JAMA (2005) 294:2581-2586.
   PubMed Web of Science ®Google Scholar
• KERSTEN S, DESVERGNE B, WAHLI W: Roles of PPARs in health and disease. Nature (2000) 405:421-424.
   PubMed Web of Science ®Google Scholar
• SCHOONJANS K, AUWERX J: Thiazolidinediones: an update. Lancet (2000) 355:1008-1010.
   PubMed Web of Science ®Google Scholar
• DEBRIL MB, RENAUD JP, FAJAS L, AUWERX J: The pleiotropic functions of peroxisome proliferator-activated receptor γ. J. Mol. Med. (2001) 79:30-47.
   PubMed Web of Science ®Google Scholar
• DESVERGNE B, WAHLI W: Peroxisome proliferator-activated receptors: nuclear control of metabolism. Endocr. Rev. (1999) 20:649-688.
   PubMed Web of Science ®Google Scholar
• AUWERX J: PPARγ, the ultimate thrifty gene. Diabetologia (1999) 42:1033-1042.
   PubMed Web of Science ®Google Scholar
• MARX N, BOURCIER T, SUKHOVA GK, LIBBY P, PLUTZKY J: PPARgamma activation in human endothelial cells increases plasminogen activator inhibitor type-1 expression: PPARgamma as a potential mediator in vascular disease. Arterioscler. Thromb. Vasc. Biol. (1999) 19:546-551.
   PubMed Web of Science ®Google Scholar
• CHARBONNEL B, RODEN M, URQUHART R et al.: Pioglitazone elicits long-term improvements in insulin sensitivity in patients with Type 2 diabetes: comparisons with gliclazide-based regimens. Diabetologia (2005) 48:553-560.
   PubMed Web of Science ®Google Scholar
• TAN MH, GLAZER NB, JOHNS D, WIDEL M, GILMORE KJ: Pioglitazone as monotherapy or in combination with sulfonylurea or metformin enhances insulin sensitivity (HOMA-S or QUICKI) in patients with Type 2 diabetes. Curr. Med. Res. Opin. (2004) 20:723-728.
   PubMed Web of Science ®Google Scholar
• CERIELLO A, JOHNS D, WIDEL M, ECKLAND DJ, GILMORE KJ, TAN MH: Comparison of the effect of pioglitazone with metformin or sulfonylurea (monotherapy and combination therapy) on postload glycemia and composite insulin sensitivity index during an oral glucose tolerance test in patients with Type 2 diabetes. Diabetes Care (2005) 28:266-272.
   PubMedGoogle Scholar
• HANEFELD M, BRUNETTI P, SCHERNTHANER GH, MATTHEWS DR, CHARBONNEL BH; QUARTET STUDY GROUP: One-year glycemic control with a sulfonylurea plus pioglitazone versus a sulfonylurea plus metformin in patients with Type 2 diabetes. Diabetes Care (2004) 27:141-147.
   PubMed Web of Science ®Google Scholar
• WINKLER K, KONRAD T, FÜLLERT S et al.: Pioglitazone reduces atherogenic dense LDL particles in nondiabetic patients with arterial hypertension: a double-blind, placebo-controlled study. Diabetes Care (2003) 26:2588-2594.
   PubMed Web of Science ®Google Scholar
• PASCERI V, WU HD, WILLERSON JT, YEH ET: Modulation of vascular inflammation in vitro and in vivo by peroxisome proliferator-activated receptor-gamma activators. Circulation (2000) 101:235-238.
   PubMed Web of Science ®Google Scholar
• PFÜTZNER A, MARX N, LÜBBEN G et al.: Improvement of cardiovascular risk markers by pioglitazone is independent from glycemic control – results from the Pioneer Study. J. Am. Coll. Card. (2005) 45:1925-1931.
   PubMed Web of Science ®Google Scholar
• GILLIES PS, DUNN CJ: Pioglitazone. Drugs (2000) 60:333-343.
   PubMed Web of Science ®Google Scholar
• MAESHIBA Y, KIYOTA Y, YAMASHITA K, YOSHIMURA Y, MOTOHASHI M, TANAYAMA S: Disposition of the new anti-diabetic agent pioglitazone in rats, dogs and monkeys. ArzneimForsch/Drug Res. (1997) 47:1-29.
   PubMedGoogle Scholar
• HAGIWARA T: Pharmacokinetic study of AD-4833 in the elderly. Jap. J. Clin. Exp. Med. (1997) 74:1307.
   Google Scholar
• HIRAGA K: Results of clinical Phase I study on AD-4833 – single dose and repeated dose studies in healthy adult subjects. Jap. J. Clin. Exp. Med. (1997) 74:1184.
   Google Scholar
• ECKLAND DA et al.: Clinical pharmacokinetics of pioglitazone. Exp. Clin. Endocrinol. Diabetes (2000) 49(Suppl.2A):S234-S242.
   Google Scholar
• PRUEKSARITANONT T, VEGA JM, ZHAO J et al.: Interactions between simvastatin and troglitazone or pioglitazone in healthy subects. J. Clin. Pharmacol. (2001) 41:573-581.
   PubMed Web of Science ®Google Scholar
• YAMAZAKI H, SUZUKI M, TANE K, SHIMADA N, NAKAJIMA M, YOKOI T: In vitro inhibitory effects of troglitazone and its metabolites on drug oxidation activities of human cytochrome P450 isoenzymes: comparison with pioglitazone or rosiglitzone. Xenobiotica (2000) 20:61-70.
   Google Scholar
• YKI-JÄRVINEN H: Thiazolidinediones. N. Engl. J. Med. (2004) 351:1106-1118.
   PubMed Web of Science ®Google Scholar
• SCHERBAUM WA, GOKE B, GERMAN PIOGLITAZONE STUDY GROUP: Metabolic efficacy and safety of once-daily pioglitazone monotherapy in patients with Type 2 diabetes: a double-blind, placebo-controlled study. Horm. Metab. Res. (2002) 34:589-595.
   PubMed Web of Science ®Google Scholar
• ROSENBLATT S, MISKIN B, GLAZER NB, PRINCE MJ, ROBERTSON KE, PIOGLITAZONE 026 STUDY GROUP: The impact of pioglitazone on glycemic control and atherogenic dyslipidemia in patients with Type 2 diabetes mellitus. Coron. Artery Dis. (2001) 12:413-423.
   PubMed Web of Science ®Google Scholar
• ARONOFF S, ROSENBLATT S, BRAITHWAITE S, EGAN JW, MATHISEN AL, SCHNEIDER RL: Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with Type 2 diabetes: a 6-month randomized placebo-controlled dose-response study. The Pioglitazone 001 Study Group. Diabetes Care (2000) 23:1605-1611.
   PubMed Web of Science ®Google Scholar
• HERZ M, JOHNS D, REVIRIEGO J et al.: A randomized, double-blind, placebo-controlled, clinical trial of the effects of pioglitazone on glycemic control and dyslipidemia in oral antihyperglycemic medication-naive patients with Type 2 diabetes mellitus. Clin. Ther. (2003) 25:1074-1095.
   PubMed Web of Science ®Google Scholar
• PAVO I, JERMENDY G, VARKONYI TT et al.: Effect of pioglitazone compared with metformin on glycemic control and indicators of insulin sensitivity in recently diagnosed patients with Type 2 diabetes mellitus. J. Clin. Endocrinol. Metab. (2003) 88:1637-1645.
   PubMed Web of Science ®Google Scholar
• SCHERNTHANER G, MATTHEWS DR, CHARBONNEL B, HANEFELD M, BRUNETTI P, QUARTET [CORRECTED] STUDY GROUP: Efficacy and safety of pioglitazone versus metformin in patients with Type 2 diabetes mellitus: a double-blind, randomized trial. J. Clin. Endocrinol. Metab. (2004) 89:6068-6076. Erratum in: J. Clin. Endocrinol. Metab. (2005) 90:746.
   PubMed Web of Science ®Google Scholar
• TAN MH, JOHNS D, STRAND J et al.: Sustained effects of pioglitazone versus glibenclamide on insulin sensitivity, glycaemic control, and lipid profiles in patients with Type 2 diabetes. Diabet. Med. (2004) 21:859-866.
   PubMed Web of Science ®Google Scholar
• CHARBONNEL BH, MATTHEWS DR, SCHERNTHANER G, HANEFELD M, BRUNETTI P, QUARTET STUDY GROUP: A long-term comparison of pioglitazone and gliclazide in patients with Type 2 diabetes mellitus: a randomized, double-blind, parallel-group comparison trial. Diabet. Med. (2005) 22:399-405.
   PubMed Web of Science ®Google Scholar
• PFÜTZNER A, HOHBERG C, LÜBBEN G et al.: Pioneer study: PPARγ-activation results in an overall improvement of clinical and metabolic markers associated with insulin resistance independent from long-term glucose control. Horm. Metab. Res. (2005) 37:510-515.
   PubMed Web of Science ®Google Scholar
• GÖKE B; GERMAN PIOGLITAZONE STUDY GROUP: Improved glycemic control and lipid profile in a randomized study of pioglitazone compared with acarbose in patients with Type 2 diabetes mellitus. Treat. Endocrinol. (2002) 1:329-36.
   PubMedGoogle Scholar
• KIPNES MS, KROSNICK A, RENDELL MS, EGAN JW, MATHISEN AL, SCHNEIDER RL: Pioglitazone hydrochloride in combination with sulfonylurea therapy improves glycemic control in patients with Type 2 diabetes mellitus: a randomized, placebo-controlled study. Am. J. Med. (2001) 111:10-17.
   PubMed Web of Science ®Google Scholar
• DEROSA G, CICERO AF, GADDI A et al.: A comparison of the effects of pioglitazone and rosiglitazone combined with glimepiride on prothrombotic state in Type 2 diabetic patients with the metabolic syndrome. Diabetes Res. Clin. Pract. (2005) 69:5-13.
   PubMed Web of Science ®Google Scholar
• EINHORN D, RENDELL M, ROSENZWEIG J, EGAN JW, MATHISEN AL, SCHNEIDER RL: Pioglitazone hydrochloride in combination with metformin in the treatment of Type 2 diabetes mellitus: a randomized, placebo-controlled study. The Pioglitazone 027 Study Group. Clin. Ther. (2000) 22:1395-1409.
   PubMed Web of Science ®Google Scholar
• MATTHEWS DR, CHARBONNEL BH, HANEFELD M, BRUNETTI P, SCHERNTHANER G: Long-term therapy with addition of pioglitazone to metformin compared with the addition of gliclazide to metformin in patients with Type 2 diabetes: a randomized, comparative study. Diabetes Metab. Res. Rev. (2005) 21:167-174.
   PubMed Web of Science ®Google Scholar
• JOVANOVIC L, HASSMAN DR, GOOCH B et al.: Treatment of Type 2 diabetes with a combination regimen of repaglinide plus pioglitazone. Diabetes Res. Clin. Pract. (2004) 63:127-34.
   PubMed Web of Science ®Google Scholar
• ROSENSTOCK J, EINHORN D, HERSHON K, GLAZER NB, YU S, PIOGLITAZONE 014 STUDY GROUP: Efficacy and safety of pioglitazone in Type 2 diabetes: a randomised, placebo-controlled study in patients receiving stable insulin therapy. Int. J. Clin. Pract. (2002) 56:251-257.
   PubMed Web of Science ®Google Scholar
• MATTOO V, ECKLAND D, WIDEL M et al.: Metabolic effects of pioglitazone in combination with insulin in patients with Type 2 diabetes mellitus whose disease is not adequately controlled with insulin therapy: results of a six-month, randomized, double-blind, prospective, multicenter, parallel-group study. Clin. Ther. (2005) 27:554-567.
   PubMed Web of Science ®Google Scholar
• GEGICK CG, ALTHEIMER MD: Comparison of effects of thiazolidinediones on cardiovascular risk factors: observations from a clinical practice. Endocr. Pract. (2001) 7:162-169. Erratum in: Endocr. Pract. (2001) 7:330.
   PubMedGoogle Scholar
• KHAN MA, ST PETER JV, XUE JL: A prospective, randomized comparison of the metabolic effects of pioglitazone or rosiglitazone in patients with Type 2 diabetes who were previously treated with troglitazone. Diabetes Care (2002) 25:708-711.
   PubMed Web of Science ®Google Scholar
• KING AB: A comparison in a clinical setting of the efficacy and side effects of three thiazolidinediones (letter). Diabetes Care (2000) 23:557.
   PubMed Web of Science ®Google Scholar
• MARTENS FM, VISSEREN FL, LEMAY J, DE KONING EJ, RABELINK TJ: Metabolic and additional vascular effects of thiazolidinediones. Drugs (2002) 62:1463-1480.
   PubMed Web of Science ®Google Scholar
• FORST T, LÜBBEN G, HOHBERG C et al.: Influence of glucose control and improvement of insulin resistance on microvascular blood flow and endothelial function in patients with diabetes mellitus Type 2. Microcirculation (2005) 12:543-550.
   PubMed Web of Science ®Google Scholar
• NEGRO R, DAZZI D, HASSAN H, PEZZAROSSA A: Pioglitazone reduces blood pressure in non-dipping diabetic patients. Minerva Endocrinol. (2004) 29:11-17.
   PubMedGoogle Scholar
• FÜLLERT S, SCHNEIDER F, HAAK E et al.: Effects of pioglitazone in nondiabetic patients with arterial hypertension: a double-blind, placebo-controlled study. J. Clin. Endocrinol. Metab. (2002) 87:5503-5506.
   PubMed Web of Science ®Google Scholar
• PAHLER S, LÜBBEN G, ROTH W, GRABELLUS M, FORST T, PFÜTZNER A: Pioglitazone decreases blood bressure in patients with Type 2 diabetes under daily routine conditions independent from anti-hypertensive treatment (Abstr.). Diabetes (2005) 54(Suppl.1):A131.
   Google Scholar
• NAKAMURA T, MATSUDA T, KAWAGOE Y et al.: Effect of pioglitazone on carotid intima-media thickness and arterial stiffness in Type 2 diabetic nephropathy patients. Metabolism (2004) 53:1382-1386.
   PubMed Web of Science ®Google Scholar
• KOSHIYAMA H, SHIMONO D, KUWAMURA N, MINAMIKAWA J, NAKAMURA Y: Rapid communication: inhibitory effect of pioglitazone on carotid arterial wall thickness in Type 2 diabetes. J. Clin. Endocrinol. Metab. (2001) 86:3452-3456.
   PubMed Web of Science ®Google Scholar
• SIDHU JS, KAPOSZTA Z, MARKUS HS, KASKI JC: Effect of rosiglitazone on common carotid intima-media thickness progression in coronary artery disease patients without diabetes mellitus. Arterioscler. Thromb. Vasc. Biol. (2004) 24:930-934.
   PubMed Web of Science ®Google Scholar
• HETZEL J, BALLETSHOFER B, RITTIG K et al.: Rapid effects of rosiglitazone treatment on endothelial function and inflammatory biomarkers. Arterioscler. Thromb. Vasc. Biol. (2005) 25:1804-1809.
   PubMed Web of Science ®Google Scholar
• LANGENFELD M, FORST T, HOHBERG C et al.: Pioglitazone decreases carotid intima-media thickness independent of glycemic control in patients with Type 2 diabetes mellitus. Circulation (2005) 111:2525-2531.
   PubMed Web of Science ®Google Scholar
• FORST T, HOHBERG C, FUELLERT S et al.: Pharmacological PPARγ stimulation in contrast to beta cell stimulation results in an improvement in adiponectin and proinsulin intact levels and reduces intima media thickness in patients with Type 2 diabetes. Horm. Metab. Res. (2005) 37:521-527.
   PubMedGoogle Scholar
• PFÜTZNER A, KUNT T, MONDOK A et al.: Fasting intact proinsulin is a highly specific predictor of insulin resistance in Type 2 diabetes. Diabetes Care (2004) 27:682-687.
   PubMed Web of Science ®Google Scholar
• DORMANDY JA, CHARBONNEL B, ECKLAND EJA et al.: On behalf of the Proactive investigators. Secondary prevention of macrovascular events in patients with Type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet (2005) 366:1279-1289.
   PubMed Web of Science ®Google Scholar
• CHARBONNEL B, DORMANDY J, ERDMANN E, MASSI-BENEDETTI M, SKENE A, PROACTIVE STUDY GROUP: The prospective pioglitazone clinical trial in macrovascular events (PROactive): can pioglitazone reduce cardiovascular events in diabetes? Study design and baseline characteristics of 5238 patients. Diabetes Care (2004) 27:1647-1653.
   PubMed Web of Science ®Google Scholar
• HANEFELD M, BELCHER G: Safety profile of pioglitazone. Int. J. Clin. Pract. Suppl. (2001) 121:27-31.
   Google Scholar
• NIEMEYER NV, JANNEY LM: Thiazolidine – induced edema. Pharmacotherapy (2002) 22:924-929.
   PubMed Web of Science ®Google Scholar
• BELCHER G, SCHERNTHANER G: Changes in liver tests during 1-year treatment of patients with Type 2 diabetes with pioglitazone, metformin or gliclazide. Diabet. Med. (2005) 22:973-979.
   PubMed Web of Science ®Google Scholar
• FARLEY-HILLS E, SIVASANKAR R, MARTIN M: Fatal liver failure associated with piogliotazone. Br. Med. J. (2004) 329:429.
   PubMed Web of Science ®Google Scholar
• NAGASAKA S, ABE T, KAWAKAMI T et al.: Pioglitazone-induced hepatic injury in a patient previously receiving troglitazone with success. Diabet. Med. (2002) 19:347-348.
   PubMedGoogle Scholar
• MAY LD, LEVKOWITCH JH, KRAM MT et al.: Mixed hepatocellular-cholestatic liver injury after pioglitazone therapy. Ann. Intern. Med. (2002) 136:449-452.
   PubMed Web of Science ®Google Scholar
• RUBIN CJ et al.: Pioglitazone liver enzyme profile is similiar to placebo in US controlled clinical trials. Diabetes (2000) 49:500.
   PubMedGoogle Scholar
• MARCY TR, BRITTON ML, BLEVINS SM: Second generation thiazolidinediones and hepatotoxicity. Ann. Pharmacother. (2004) 38:1419-1423.
   PubMed Web of Science ®Google Scholar
• TAN MH, BAKSI A, KRAHULEC B et al.: Comparison of pioglitazone and gliclazide in sustaining glycemic control over 2 years in patients with Type 2 diabetes. Diabetes Care (2005) 28:544-549.
   PubMed Web of Science ®Google Scholar
• BELCHER G et al.: Weight changes with treatment of Type 2 diabetes with pioglitazone, metformin and gliclazide. Diabetes (2003) 52(Suppl.1):(Abstr. 474-P).
   Google Scholar
• MIYAZAKI Y, MAHANKALI A, MATSUDA M et al.: Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in Type 2 diabetic patients. J Clin. Endocrinol. Metab (2002) 87:2784-2791.
   PubMed Web of Science ®Google Scholar
• PAHLER S, PFÜTZNER A, NGUYEN M et al.: IRIS III-Study: pioglitazone improves metabolic control and blood pressure in patients with Type 2 diabetes without increase in body weight (abstract). Diabetes (2005) 54(Suppl.1):A527.
   PubMedGoogle Scholar
• YKI-JÄRVINEN H: The PROactive study: some answers, many questions. Lancet (2005) 366:1241-1242.
   PubMed Web of Science ®Google Scholar
• KARTER AJ, AHMED AT, LIU J, MOFFET HH, PARKER MM: Pioglitazone initiation and subsequent hospitalization for congestive heart failure. Diabet. Med. (2005) 22:986-993.
   PubMed Web of Science ®Google Scholar
• RAJAGOPALAN R, ROSENSON RS, FERNANDES AW, KHAN M, MURRAY FT: Association between congestive heart failure and hospitalization in patients with Type 2 diabetes mellitus receiving treatment with insulin or pioglitazone: a retrospective data analysis. Clin. Ther. (2004) 26:1400-1410.
   PubMed Web of Science ®Google Scholar
• MASOUDI FA, INZUCCHI SE, WANG Y, HAVRANEK EP, FOODY JM, KRUMHOLZ HM: Thiazolidinediones, metformin, and outcomes in older patients with diabetes and heart failure: an observational study. Circulation (2005) 111:583-590.
   PubMed Web of Science ®Google Scholar
• SCANDINAVIAN SIMVASTATIN SURVIVAL STUDY GROUP: Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease and diabetes or impaired fasting glucose levels. Arch. Intern. Med. (1994) 344:1383-1389.
   Google Scholar
• KEECH A, COLQUHOUN D, BEST J et al.: Secondary prevention of cardiovascular events with long-term pravastatin in patients with diabetes or impaired fasting glucose: results from the LIPID trial. Diabetes Care (2003) 26:2713-2721.
   PubMed Web of Science ®Google Scholar
• GOLDBERG RB, MELLIES MJ, SACKS FM et al.: Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant survivors of myocardial infarction survivors with average cholesterol levels. Subgroup analyses in the cholesterol and recurrent events (CARE) trial. Circulation (1998) 98:2513-2519.
   PubMed Web of Science ®Google Scholar
• HEART OUTCOME PREVENTION EVALUATION (HOPE) STUDY INVESTIGATORS: Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet (2000) 355:253-259.
   PubMed Web of Science ®Google Scholar
• LÜBBEN G, FENNENKÖTTER U, WEIDENHAMMER J et al.: The COMPACT-study: pioglitazone vs. insulin for treatment of patients with Type 2 diabetes mellitus: a medical and pharmacoeconomic analysis. Poster presented at the 6th Annual International Society For Pharmacoeconomics and Outcomes Research European Congress. Barcelona, Spain (9 - 11 November 2003).
   Google Scholar